Clinical Trial

Emapalumab Efficacy in Children With Primary Hemophagocytic Lymphohistiocytosis

Study acronym: CGM EMA
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this retrospective study is to assess efficacy and safety of emapalumab prescribed for the treatment in children with refractory from of pHLH.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-05.
Trial Details
NCT Number NCT06587191
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions Primary Hemophagocytic Lymphohistiocytosis
Enrollment 7 participants
Start Date 2024-08-01
Primary Completion 2024-09-01 (estimated)
Study Completion 2024-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-01